Background illustration for clinical trials search

Paid Clinical Trials El Paso

Discover 867 paid clinical trials in El Paso, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 867

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

for

Relapsed or Refractory Large B-cell Lymphoma

Location: Denver CO, Goodyear AZ, Austin TX, St Louis MO,

Sponsor: Kite, A Gilead Company

Sex: All

Age: 18+

Code: NCT07479797

Phase3, Recruiting

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

for

Polycythemia Vera (PV), Myelofibrosis (MF),

Location: Denver CO, Houston TX, Nashville TN, Grand Rapids MI,

Sponsor: Prelude Therapeutics

Sex: All

Age: 18+

Code: NCT07469891

Phase1, Recruiting

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

for

Multiple Myeloma

Location: Denver CO, Salt Lake City UT, Kansas City KS,

Sponsor: Janssen Research & Development, LLC

Sex: All

Age: 18+

Code: NCT07258511

Phase3, Recruiting

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

for

Chronic Lymphocytic Leukemia (CLL),

Location: Denver CO, Salt Lake City UT, Iowa City IA, Austin TX,

Sponsor: Nurix Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07221500

Phase2, Recruiting

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

for

Large B-cell Lymphoma, Lymphoma, B-Cell,

Location: Denver CO, Aurora CO, Salt Lake City UT, Omaha NE,

Sponsor: Lyell Immunopharma, Inc.

Sex: All

Age: 18+

Code: NCT07188558

Phase3, Recruiting

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

for

Head and Neck Squamous Cell Carcinoma HNSCC,

Location: Denver CO, Austin TX, San Antonio TX, San Diego CA,

Sponsor: Sutro Biopharma, Inc.

Sex: All

Age: 18+

Code: NCT07227168

Phase1, Recruiting

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

for

Acute Myeloid Leukemia (AML)

Location: Denver CO, Aurora CO, Albuquerque NM, Gilbert AZ,

Sponsor: Kura Oncology, Inc.

Sex: All

Age: 18+

Code: NCT07007312

Phase3, Recruiting

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

for

Myeloproliferative Neoplasms

Location: Denver CO, Salt Lake City UT, Phoenix AZ, Dallas TX,

Sponsor: Incyte Corporation

Sex: All

Age: 18+

Code: NCT07008118

Phase1, Recruiting

A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

for

Solid Tumor Malignancies

Location: Denver CO, Salt Lake City UT, Irving TX, Austin TX,

Sponsor: Kumquat Biosciences Inc.

Sex: All

Age: 18+

Code: NCT07207707

Phase1, Recruiting

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

for

AML, MDS

Location: Denver CO, Aurora CO, Dallas TX, Austin TX, Duarte CA,

Sponsor: TScan Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07702578

Phase3, Recruiting

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

for

Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)

Location: Denver CO, Dallas TX, Iowa City IA, Madison WI,

Sponsor: SCRI Development Innovations, LLC

Sex: All

Age: 19+

Code: NCT06974786

Phase2, Recruiting

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

for

T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma

Location: Denver CO, St Louis MO, San Antonio TX, Duarte CA,

Sponsor: Allotera Therapeutics

Sex: All

Age: 0+

Code: NCT06514794

Phase2, Recruiting

Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM

for

Waldenstrom Macroglobulinemia

Location: Denver CO, Dallas TX, Boston MA

Sponsor: Massachusetts General Hospital

Sex: All

Age: 18+

Code: NCT06561347

Phase2, Recruiting

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

for

Hematologic Malignancies, Inherited Disorders of Metabolism,

Location: Denver CO, Aurora CO, Salt Lake City UT, Omaha NE,

Sponsor: Center for International Blood and Marrow Transplant Research

Sex: All

Age: 0+

Code: NCT01351545

Recruiting

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

for

Myelofibrosis

Location: Denver CO, Salt Lake City UT, Tucson AZ, Minneapolis MN,

Sponsor: Sumitomo Pharma America, Inc.

Sex: All

Age: 18+

Code: NCT04176198

Phase1, Phase2, Recruiting

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

for

Multiple Myeloma

Location: Denver CO, Aurora CO, Phoenix AZ, San Diego CA,

Sponsor: European Myeloma Network B.V.

Sex: All

Age: 18+

Code: NCT05243797

Phase3, Recruiting

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

for

Multiple Myeloma

Location: Denver CO, Orange CA, Los Angeles CA, Houston TX,

Sponsor: Regeneron Pharmaceuticals

Sex: All

Age: 18+

Code: NCT05828511

Phase1, Phase2, Recruiting

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

for

Hematologic Malignancies, Waldenstroms Macroglobulinaemia,

Location: Denver CO, Springdale AR, Dallas TX, Spokane WA,

Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT04728893

Phase2, Recruiting

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

for

B-cell Acute Lymphoblastic Leukemia

Location: Denver CO, Aurora CO, Austin TX, San Antonio TX,

Sponsor: Cellectis S.A.

Sex: All

Age: 15 - 50

Code: NCT04150497

Phase1, Phase2, Recruiting

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

for

AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar,

Location: Denver CO, Omaha NE, Oklahoma City OK, Kansas City KS,

Sponsor: Kura Oncology, Inc.

Sex: All

Age: 18+

Code: NCT06001788

Phase1, Recruiting

Paid Clinical Trials El Paso

Filter results

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Interested in new trials?

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia